Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot International flag

This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot2: STU1 Ballot 2) based on FHIR (HL7® FHIR® Standard) v6.0.0. No current official version has been published yet. For a full list of available versions, see the Directory of published versions

: SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer - JSON Representation

Raw json | Download

{
  "resourceType" : "Group",
  "id" : "179619",
  "meta" : {
    "versionId" : "5",
    "lastUpdated" : "2025-03-15T21:15:32.464Z",
    "profile" : [
      🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/systematic-review-eligibility-criteria"
    ]
  },
  "text" : {
    "status" : "empty",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
  },
  "extension" : [
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/artifact-author",
      "valueContactDetail" : {
        "name" : "Brian S. Alper"
      }
    },
    {
      "url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/cite-as",
      "valueMarkdown" : "SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer [Database Entry: FHIR Group Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179619. Revised 2023-12-06. Available at: https://fevir.net/resources/Group/179619. Computable resource at: https://fevir.net/resources/Group/179619#json."
    }
  ],
  "url" : "https://fevir.net/resources/Group/179619",
  "identifier" : [
    {
      "type" : {
        "coding" : [
          {
            "system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
            "code" : "ACSN",
            "display" : "Accession ID"
          }
        ],
        "text" : "FEvIR Object Identifier"
      },
      "system" : "urn:ietf:rfc:3986",
      "value" : "https://fevir.net/FOI/179619",
      "assigner" : {
        "display" : "Computable Publishing LLC"
      }
    }
  ],
  "name" : "SystematicReviewEligibilityCriteria_ADT_and_Docetaxel_vs_ADT_alone_for_metastatic_hormone_naive_prostate_cancer",
  "title" : "SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer",
  "status" : "active",
  "publisher" : "Computable Publishing LLC",
  "contact" : [
    {
      "telecom" : [
        {
          "system" : "email",
          "value" : "support@computablepublishing.com"
        }
      ]
    }
  ],
  "description" : "**Study selection criteria**\nTypes of Studies.\nRandomized controlled clinical trials (RCTs) with parallel design that compared the association of ADT and chemotherapy (docetaxel), versus ADT alone.\n\nTypes of participants.\nPatients aged ≥18 years with cytological or histological diagnosis of mHNPC.",
  "useContext" : [
    {
      "code" : {
        "system" : "https://fevir.net/resources/CodeSystem/179423",
        "code" : "evidence-communication",
        "display" : "Evidence Communication"
      },
      "valueCodeableConcept" : {
        "coding" : [
          {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "SystematicReviewEligibilityCriteria",
            "display" : "SystematicReviewEligibilityCriteria"
          }
        ]
      }
    }
  ],
  "copyright" : "https://creativecommons.org/licenses/by-nc-sa/4.0/",
  "membership" : "conceptual",
  "combinationMethod" : "all-of",
  "characteristic" : [
    {
      "code" : {
        "text" : "Study Design"
      },
      "valueCodeableConcept" : {
        "coding" : [
          {
            "system" : "https://fevir.net/sevco",
            "code" : "SEVCO:01003",
            "display" : "randomized assignment"
          }
        ]
      },
      "exclude" : false,
      "description" : "Randomized controlled clinical trials (RCTs)"
    },
    {
      "code" : {
        "text" : "Study Design"
      },
      "valueCodeableConcept" : {
        "coding" : [
          {
            "system" : "https://fevir.net/sevco",
            "code" : "SEVCO:01011",
            "display" : "Parallel cohort design"
          }
        ]
      },
      "exclude" : false,
      "description" : "parallel design"
    },
    {
      "code" : {
        "text" : "Comparison"
      },
      "valueReference" : {
        "type" : "EvidenceVariable",
        "display" : "GroupAssignment: ADT plus docetaxel vs. ADT alone"
      },
      "exclude" : false,
      "description" : "compared the association of ADT and chemotherapy (docetaxel), versus ADT alone"
    },
    {
      "code" : {
        "coding" : [
          {
            "system" : "http://snomed.info/sct",
            "code" : "397669002",
            "display" : "Age"
          }
        ]
      },
      "valueQuantity" : {
        "value" : 18,
        "comparator" : ">=",
        "unit" : "years",
        "system" : "http://unitsofmeasure.org",
        "code" : "a"
      },
      "exclude" : false,
      "description" : "Types of participants.\nPatients aged ≥18 years",
      "method" : [
        {
          "text" : "applied to participants in the studies"
        }
      ]
    },
    {
      "code" : {
        "coding" : [
          {
            "system" : "http://snomed.info/sct",
            "code" : "64572001",
            "display" : "Disease (disorder)"
          }
        ]
      },
      "valueCodeableConcept" : {
        "text" : "metastatic hormone-naive prostate cancer"
      },
      "exclude" : false,
      "description" : "Types of participants.\nPatients with cytological or histological diagnosis of mHNPC.",
      "method" : [
        {
          "text" : "applied to participants in the studies"
        },
        {
          "text" : "cytological or histological diagnosis"
        }
      ]
    }
  ]
}